安立生坦（Myogen）。
Ambrisentan (Myogen).
作者信息
Billman George E
机构信息
Department of Physiology and Cell Biology The Ohio State University, Columbus 43210-1218, USA.
出版信息
Curr Opin Investig Drugs. 2002 Oct;3(10):1483-6.
PMID:12431023
Abstract
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan had entered phase II trials for chronic heart failure, hypertension, kidney failure and pulmonary hypertension.
摘要
安立生坦（LU - 208075，BSF - 208075）和LU - 302146（BSF - 302146）正由麦奥基因公司（Myogen）根据雅培公司（前身为巴斯夫制药公司）的许可进行研发，用于潜在治疗缺血后急性肾衰竭和心血管疾病。截至2001年8月，安立生坦已进入慢性心力衰竭、高血压、肾衰竭和肺动脉高压的II期试验。
Zotero 插件